Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

Clinical Trials

SELECT-CAR-NK

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

TIL Therapy for Metastatic Renal Cell Carcinoma

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

High Dose IL 2 and Entinostat in RCC

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

UVA-AM-002

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

RENALVax-2

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Interleukin-2 in Metastatic Kidney Cancer

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Vaccine Treatment of Kidney Cancer

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer

ROSORC

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis